GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
March 26, 2024 17:00 ET
|
GT Biopharma, Inc.
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting
November 03, 2022 09:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update
October 31, 2022 17:15 ET
|
GT Biopharma, Inc.
Announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)$20.8 million in cash, cash equivalents and short-term investments as of September 30,...